Efficacy of Satawar (Asparagus racemosus) in enhancing serum AMH levels among women with Diminished ovarian reserve
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 20
- Locations
- 1
Study Overview
Brief Summary
Diminished Ovarian Reserve (DOR) is a common cause of infertility in women of reproductive age and is characterized by low serum Anti-Müllerian Hormone (AMH) levels. Satawar (Asparagus racemosus) is a classical Unani drug traditionally used to improve female reproductive health and ovarian function.
This study is a prospective, open-label, single-arm interventional clinical trial conducted to evaluate the efficacy of Satawar in improving serum AMH levels among women with Diminished Ovarian Reserve. Twenty women aged 20–40 years with serum AMH levels less than 1.0 ng/mL will be enrolled after obtaining written informed consent.
Participants will receive oral Safoof-e-Satawar at a dose of 6 g/day (3 g twice daily) with lukewarm milk for a period of 90 days. The primary outcome measure is change in serum AMH levels assessed at baseline and at Day 90. Secondary outcomes include assessment of menstrual regularity, antral follicle count, ovarian volume, and safety of the intervention.
The study aims to provide clinical evidence for the role of Satawar in improving ovarian reserve in women with Diminished Ovarian Reserve.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Masking
- None
Eligibility Criteria
- Ages
- 20.00 Year(s) to 40.00 Year(s) (—)
- Sex
- Female
Inclusion Criteria
- •Female patients aged between 20 and 40 years.
- •Serum amh levels below 1.0 ng/mL.
- •Regular menstrual cycle or oligo/irregular cycles.
- •Patients with Amenorrhea.
- •Infertile patients.
- •Willing to participate and sign the written informed consent.
- •Fit to take oral Unani medications for the duration of the study.
Exclusion Criteria
- •Known systemic disorders such as tuberculosis, or malignancy.
- •Menopause women’s.
- •Women with comorbidities.
- •Patients undergoing assisted reproductive technologies (ART) concurrently.
- •Pregnant or lactating women.
- •Hypersensitivity to the drug Administration.
Investigators
Dr Umme Aman Saba
Government Nizamia Tibbi College And General Hospital